<DOC>
	<DOC>NCT02445053</DOC>
	<brief_summary>To describe the effectiveness of KalydecoÂ® treatment in patients with cystic fibrosis (CF) who have 1 of 8 non G551D gating CFTR mutations (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D).</brief_summary>
	<brief_title>Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male or female with confirmed diagnosis of CF16 At least 1 allele with 1 of the following CFTR mutations: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D Six years of age or older on the date of signed (Informed Consent Form) ICF, and where appropriate, date of assent Signed ICFs and, where appropriate, signed Assent Form Able to understand the study requirements and comply with study data collection procedures Previously exposed to Kalydeco, except currently treated patients who started Kalydeco treatment within 6 months of enrollment Currently enrolled in a Kalydeco interventional study or other interventional therapeutic clinical study directed at CFTR modulation History of organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>